Acquisizione competenze di processo:First, to increase knowledge about disease pathogenesis with a focus on the biology of circulating tumor cells, responsible for dissemination and extramedullary disease, and minimal residual disease clones who represent the reservoir of clonal evolution and disease recurrence. second, to consider undetectable measurable residual disease (mrd), defined by high-sensitive techniques, as the new endpoint of therapy. third, to treat disease causation instead of symptomatology through early detection and intervention. If cure is the objective of treating patients with active mm, offering intensive therapies to high-risk patients and a gentle approach to standard risk patients may be a wrong philosophy.